The molecule has the property of optimizing the microcirculatory function. In fact, it reduces capillary permeability both by stabilizing the basement membrane for an action on the collagen chains that constitute it, and by interacting with different biochemical mediators that favor endothelial permeability itself. In this way it favors a reduction in blood hyperviscosity and also performs an anti- platelet aggregation action.
Pharmacokinetics
Calcium dobesilate after oral administration is well absorbed from the gastrointestinal tract. Maximum plasma concentrations of 6-8 µg / ml are reached approximately six hours after oral administration of 500 mg, which are generally maintained for over 12 hours. In the body the drug is poorly metabolized and its binding with plasma proteins is rather low. Elimination occurs mainly through excretion from the renal excretion.
Clinical uses
Calcium dobesilate is indicated in states of fragility and altered capillary permeability, e.g. diabetic retinopathy, chronic venous disease and hemorrhoidal disease. In combination with lidocaine or with lidocaine and dexamethasone, the drug enters the composition of preparations for the therapy of hemorrhoidal disease. In association with potassium hydrodex-sulfate enters the composition of adjuvant gels in the treatment of varicose veins. The efficacy of calcium dobesilate has been described in patients with microangiopathies such as diabetic retinopathy and diabetic nephropathy.
Side effects
During treatment, gastrointestinal disorders can be observed: dyspepsia, nausea, vomiting, diarrhea. These disorders generally regress with the simple decrease in the dose taken, or with the temporary suspension of the treatment. Other adverse events related to hypersensitivity reactions have also been reported : among these skin rashes, skin rash, fever, arthralgia. Rare cases of agranulocytosis have also been reported in medical literature. The rarity of the latter adverse effect led several authors to conclude that perhaps there could have been methodological errors in risk assessments.
Contraindications
The drug is contraindicated in subjects with known hypersensitivity to the active ingredient or to any of the inactive ingredients contained in the pharmaceutical formulation. It is also contraindicated in women who are pregnant and breastfeeding.
Therapeutic doses
Calcium dobesilate is administered orally at a daily dose of 0.5-2 g. It can also be administered rectally in the case of hemorrhoidal disease.
